CPhI 2014 Experts Statements: John Nicols, President and CEO, Codexis

3. Which new business models, like project-based or value-based outsourcing, could turn out to be the most promising guarantors for a successful cooperation with the pharmaceutical industry?

In addition to project-based business models, Codexis offers a deeply collaborative licensing model to partners that enables not only faster delivery but also parallel capabilities for cooperation. These types of elite partnerships offer truly synergistic relationships that can teach both sides, empowering both partners to explore new boundaries and push the cooperation beyond that which each partner could achieve alone.

This is a new type of business model that effectively forms an alliance of the world's best protein engineers in collaboration, where Codexis and the licensee work together to develop better proteins for more and more applications. We have just entered into such an arrangement with GSK, licensing them our CodeEvolver protein engineering technology. This approach will generate findings that can also benefit other companies in the industry moving forward.